BioAffinity Technologies partnered with Pictor to develop high-throughput sputum-based laboratory-developed tests for assessing lung inflammation in asthma and chronic obstructive pulmonary disease. The collaboration combines BioAffinity’s flow cytometry expertise with Pictor’s targeted proteomics platform to analyze immune cells and cytokine profiles tied to airway inflammation pathways. Financial terms were not disclosed, and the firms plan to retain and allocate intellectual property across the underlying flow cytometry protocol versus targeted proteomics platform innovations.